Fundraising Fox
Vivoryon
1 known investors
Find your way into Vivoryon
Sign up to see every warm intro you have to Vivoryon
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Vivoryon team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Vivoryon is a biotech company focused on developing therapeutics, with a leadership team experienced in pharmaceutical development, clinical research, and life sciences business operations.
Founders & leadership
JN
Julia NeugebauerChief Operating Officer, Executive DirectorJulia Neugebauer held the role of Vice President and Global Head of Investor Relations at MorphoSys AG before becoming Chief Operating Officer at Vivoryon Therapeutics, bringing nearly two decades of biotech industry experience in investor relations and operational management across U.S. and international markets.
MS
Michael SchaefferChief Business Officer, Executive DirectorMichael Schaeffer is Chief Business Officer and Executive Director at Vivoryon, a biotech company developing therapeutics.
Investors · 1
Related companies · 6
Vividion TherapeuticsVividion Therapeutics develops small molecule therapeutics using a covalent-first chemoproteomics approach to identify and target previously undruggable proteins. The company operates across the full drug development spectrum from discovery to clinical development.
Esperion TherapeuticsBiopharma developing HDL-C regulating therapies; listed 2000.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Regeneron NASDAQ: REGN www.regeneron.comRegeneron is a biotechnology company that develops medicines ranging from biologics to genetic medicines to treat serious diseases across areas such as metabolic disease, ophthalmology, and rare disease. The company focuses on research and development driven by human biology, with a clinical trial pipeline addressing conditions like generalized myasthenia gravis.
Viridian TherapeuticsViridian Therapeutics develops treatments for thyroid eye disease, a rare autoimmune condition affecting the eyes and orbit. The company focuses on clinical development and patient support programs in the biotech sector.
virionVirion Therapeutics develops CD8+ T cell-based immunotherapies using genetically encoded checkpoint modifiers delivered with target-specific antigens via a viral vector platform, targeting cancers and chronic infectious diseases. Its lead product, VRON-0200, is in clinical development as a potential functional cure for chronic hepatitis B.
Companies working in the same space as Vivoryon.
In the news
Frequently asked questions
- What does Vivoryon do?
- Vivoryon is a biotech company focused on developing therapeutics, with a leadership team experienced in pharmaceutical development, clinical research, and life sciences business operations.
- Who are Vivoryon's investors?
- Vivoryon's investors include Andera Partners.